EAI-045

EAI-045 Structure
CAS No.
1942114-09-1
Chemical Name:
EAI-045
Synonyms
EA1045;EAI-045;CS-2350;EAI 045;EAI-045;EAI045;EAI 045;EAI-045;2-(5-fluoro-2-hydroxyphenyl)-2-(1-oxoisoindolin-2-yl)-N-(thiazol-2-yl)acetamide;α-(5-fluoro-2-hydroxyphenyl)-1,3-dihydro-1-oxo-N-2-thiazolyl-2H-Isoindole-2-acetamide;2H-Isoindole-2-acetamide,α-(5-fluoro-2-hydroxyphenyl)-1,3-dihydro-1-oxo-N-2-thiazolyl-;N-(3-((5-fluoroethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide (EAI-045);2H-Isoindole-2-acetamide, α-(5-fluoro-2-hydroxyphenyl)-1,3-dihydro-1-oxo-N-2-thiazolyl-
CBNumber:
CB83122752
Molecular Formula:
C19H14FN3O3S
Molecular Weight:
383.4
MOL File:
1942114-09-1.mol
Modify Date:
2024/7/2 8:55:24

EAI-045 Properties

Density 1.546±0.06 g/cm3(Predicted)
storage temp. 2-8°C
solubility ≥38.3 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
form solid
pka 7.20±0.50(Predicted)
color White to khaki

SAFETY

Risk and Safety Statements

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H302-H315-H319-H335
Precautionary statements  P261-P305+P351+P338
NFPA 704
0
2 0

EAI-045 Chemical Properties,Uses,Production

Description

EAI045 is a potent and selective EGFR inhibitor (fourth generation). EAI045 targets selected drug-resistant EGFR mutants without affecting the wild-type receptor. EAI045 inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochemical assays. Therefore, it is a potential candidate drug for the treatment of related non-small cell lung cancer (NSCLC). It should be noted that EAI-045 is effectively in targeting the EGFR C797S mutation, which is resistance to the third-generation EGFR inhibitors including AZD9291 (osimertinib) and CO-1686 (rociletinib).

Uses

Epidermal growth factor receptor (EGFR) is a cell surface receptor often mutated in cancer cells. α-?(5-Fluoro-?2-?hydroxyphenyl)?-?1,?3-?dihydro-?1-?oxo-?N-?2-?thiazolyl-2H-?isoindole-?2-?acetamide is an allosteric EGFR inhibitor that is selective against drug-resistant EGFR mutants.

References

Wang, S., Y. Song, and D. Liu. "EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance." Cancer Letters385(2017):51.
Jia, Y., et al. "Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors:." Nature 534.7605(2016):129.

EAI-045 Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 139)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
A.J Chemicals 91-9810153283 New Delhi, India 6124 58 Inquiry
ATK CHEMICAL COMPANY LIMITED +undefined-21-51877795 China 32760 60 Inquiry
Zhejiang ZETian Fine Chemicals Co. LTD +8618957127338 China 2141 58 Inquiry
BOC Sciences +1-631-485-4226 United States 19553 58 Inquiry
career henan chemical co +86-0371-86658258 +8613203830695 China 29826 58 Inquiry
ANHUI WITOP BIOTECH CO., LTD +8615255079626 China 23556 58 Inquiry
AFINE CHEMICALS LIMITED +86-0571-85134551 China 15395 58 Inquiry
InvivoChem +1-708-310-1919 +1-13798911105 United States 6393 58 Inquiry
Wuhu Nuowei chemistry Co., Ltd. +86-0553-2911116-802 +undefined17756524438 China 1640 58 Inquiry
TargetMol Chemicals Inc. +1-781-999-5354 United States 19973 58 Inquiry

EAI-045 Spectrum

EAI-045 2-(5-fluoro-2-hydroxyphenyl)-2-(1-oxoisoindolin-2-yl)-N-(thiazol-2-yl)acetamide EA1045 α-(5-fluoro-2-hydroxyphenyl)-1,3-dihydro-1-oxo-N-2-thiazolyl-2H-Isoindole-2-acetamide EAI 045;EAI-045 CS-2350 EAI045;EAI 045;EAI-045 N-(3-((5-fluoroethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide (EAI-045) 2-(5-Fluoro-2-hydroxyphenyl)-2-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)-N-1,3-thiazol-2-ylacetamide 2H-Isoindole-2-acetamide, α-(5-fluoro-2-hydroxyphenyl)-1,3-dihydro-1-oxo-N-2-thiazolyl- 2H-Isoindole-2-acetamide,α-(5-fluoro-2-hydroxyphenyl)-1,3-dihydro-1-oxo-N-2-thiazolyl- 1942114-09-1 C19H14FN3O3S API API